Medical news today: Friday, October 30, 2026
Congo's Ebola outbreak passes 10,000 cases, US forces drug middlemen to open their books, and Israel warns on black-market weight-loss peptides
Get tomorrow's issue in your inbox.
- 01
Lilly raises 2026 revenue forecast as Mounjaro and Zepbound demand surges
Source: Reuters (via Investing.com)
Eli Lilly now expects 2026 revenue of USD 91-92 billion, up from 85-87 billion, after third-quarter revenue of USD 24.4 billion beat analyst estimates, driven by its weight-loss and diabetes injections Mounjaro and Zepbound, Reuters reports. It trimmed its adjusted profit outlook to USD 35-36 per share because of deal-related research charges; realised prices fell 15% in the quarter, partly due to Mounjaro joining China's national reimbursement list.
Why it mattersLilly is selling far more weight-loss medicine at lower average prices, a sign these drugs are becoming cheaper and more widely covered, including in China. Not investment advice. More on Obesity & metabolic →
Market news · Not investment advice
- 02
International survey finds many women have never discussed heart health with a clinician
Source: Medical Xpress
An international study found that only about half of women know heart disease is the leading cause of death in women, a risk that rises around menopause. Many had never talked about their heart with a doctor or nurse, and most reported living with several symptoms.
Why it mattersHeart disease in women is often spotted late; knowing the risk rises around menopause can prompt simple check-ups, such as blood pressure and cholesterol tests, that are far cheaper than treating a heart attack. More on Drug & device safety →
- 03
UK study finds peels and stalks often hold more fibre than the parts we eat
Source: BBC News
Researchers at King's College London report that commonly discarded parts of fruit and vegetables, such as peels, rinds, stalks and seeds, can be a valuable and overlooked source of dietary fibre. The BBC notes advice to wash produce well and to avoid parts that are unsafe to eat, such as green potatoes and rhubarb leaves.
Why it mattersMost people eat too little fibre, and using more of the food you already buy is a cheap way to get more of it while cutting waste and grocery costs.
- 04
US finalises rule forcing drug middlemen to disclose fees to employers
Source: BioPharma Dive
Starting in 2027, pharmacy benefit managers (PBMs, the companies that negotiate drug prices and run prescription plans for employers) must share a broad range of fee and compensation data with self-funded employer clients. Employers welcomed the US Labor Department rule; PBMs called it government overreach. STAT (paywall) also reports the rule.
Why it mattersEmployers who can see what middlemen earn are better placed to negotiate, which over time could affect what workers pay in premiums and at the pharmacy counter. More on Infectious disease →
Market news · Not investment advice
- 05
US judge blocks narrower 'medically frail' exemption from Medicaid work rules
Source: STAT (paywall)
A federal judge ruled that US regulators exceeded their authority when they narrowed the exceptions to Medicaid work requirements for people with medical issues. Medicaid is the US public health insurance programme for people on low incomes. Full story is STAT+ (paywall).
Why it mattersThe ruling affects which sick or disabled people can keep public health coverage without meeting work rules, which can decide whether they can afford care at all. More on Approvals & regulatory →
- 06
Genmab shares hit record after head and neck cancer drug succeeds in late-stage trial
Source: BioPharma Dive
Denmark's Genmab added more than USD 7 billion in market value after a Phase 3 (late-stage) trial suggested petosemtamab, a recently acquired antibody drug used with Keytruda, could become a new standard first treatment for a form of head and neck cancer, BioPharma Dive reports. The company said the combination improved overall survival at the first interim analysis.
Why it mattersIf regulators approve it, patients with advanced head and neck cancer could get a new first-line option. Not investment advice. More on Approvals & regulatory →
Market news · Not investment advice
- 07
Congo's Ebola outbreak tops 10,000 cases as experts warn of wider spread
Source: AP News
The Ebola outbreak in Congo passed 10,000 confirmed cases this week, and nearly half of those infected have died, AP reports. Weekly cases appear to be holding steady at a high level rather than falling; about 30 confirmed cases have appeared in other countries, including Kenya and Nigeria, and researchers say the risk outside Congo will grow if the outbreak is not controlled.
Why it mattersThis is now one of the largest Ebola outbreaks on record; travellers and health systems in Africa and beyond are on alert, and stopping it at the source is the cheapest way to prevent wider spread. More on Infectious disease →
- 08
India's free health cover for over-70s logs 23.46 lakh hospital admissions in two years
Source: ThePrint (PTI)
Ayushman Vay Vandana, which gives every Indian aged 70 and over hospital cover of up to Rs 5 lakh per family a year regardless of income, recorded 23.46 lakh authorised hospital admissions worth Rs 5,668.80 crore by 20 October 2026, according to health ministry data. Cataract surgery was the most common treatment (4.71 lakh), followed by kidney dialysis (about 2.90 lakh); coronary angioplasty (opening blocked heart arteries) had the largest value, about Rs 649 crore.
Why it mattersFor families with elderly parents in India, the scheme can cover costly operations like cataract surgery, dialysis and heart procedures without paying cash at the hospital.
- 09
Henkel raises 2026 sales outlook as hair care drives strong quarter
Source: Cosmetics Business
Henkel, the German owner of Schwarzkopf and Olaplex, raised its 2026 sales outlook after third-quarter sales rose 11% to EUR 5.7bn, helped by hair care and by both price and volume growth in its consumer business, Cosmetics Business reports.
Why it mattersGrowth from both higher prices and more units sold shows shoppers are still paying more for hair care, a sign of where beauty prices are heading. More on Pharma industry →
- 10
European supplement body issues rules for influencers to curb misleading health claims
Source: NutraIngredients
Food Supplements Europe (FSE), an industry body, issued guidelines to help brands and influencers keep supplement marketing within EU consumer protection law, covering clear ad disclosures, using only authorised health claims, checking creators and monitoring campaigns.
Why it mattersMuch supplement buying is driven by social media; clearer rules could mean fewer exaggerated claims and less money wasted on products that cannot do what influencers promise. More on Nutraceuticals & supplements →
- 11
Small trial reports weight and blood sugar improvements with combination supplement
Source: NutraIngredients
An 84-day randomised, placebo-controlled study in 87 people with overweight or obesity found SlimSEB, a supplement containing probiotics, digestive enzymes, herbal extracts and chromium, improved weight, waist size, blood sugar and cholesterol measures compared with placebo, NutraIngredients reports. No serious side effects were reported, and the researchers said larger trials are needed to confirm the results.
Why it mattersIt is one small study of a single branded product; until larger trials confirm it, shoppers should treat weight-loss supplement claims with caution. More on Obesity & metabolic →
- 12
India cancels import registration of FatX injection over fat-dissolving claims
Source: Medical Dialogues
India's drug regulator (DCGI/CDSCO) cancelled the cosmetic import registration, valid until July 2027, for FatX, a product imported by Delhi-based Tekno Midas Aesthetics. The regulator said claims that it dissolves fat cells are drug claims, and that as an injectable it does not fit India's definition of a cosmetic; the company's reply to an August show-cause notice was judged unsatisfactory.
Why it mattersFat-dissolving injections sold as 'cosmetics' skip the safety checks that drugs face, so this signals tighter action on aesthetic products that people may pay thousands of rupees for. More on Approvals & regulatory →
- 13
Israel warns against illegal peptides sold online for weight loss and bodybuilding
Source: Ynetnews
Israel's Health Ministry warned against buying unapproved peptides (short chains of amino acids sold as injections or pills) marketed for weight loss, muscle building and anti-ageing, naming BPC-157, GHK-Cu, CJC-1295, TB-500 and the experimental weight-loss drug retatrutide. It said products from unregulated sources may damage the liver and kidneys, disrupt hormones and blood sugar, cause infections, or contain unlisted contaminants; similar alerts have come from Canada and Australia.
Why it mattersHigh prices for approved weight-loss drugs are pushing people toward cheap online alternatives, and regulators say these unchecked products can carry serious, costly health risks. More on Approvals & regulatory →
- 14
FDA flags Medline's exit from all its hospital beds over fire and entrapment risks
Source: FDA
The FDA says Medline is discontinuing and withdrawing all Medline brand beds and their accessories and parts, recommending they be removed or, in some cases, corrected before further use, because of fire, electrical overheating, entrapment and suffocation risks that could cause serious injury or death. The FDA is reviewing this potentially high-risk issue.
Why it mattersThese beds are used in hospitals, care homes and home care; families of patients using one should check with their provider or supplier whether it is affected. More on Approvals & regulatory →
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
